CY1109171T1 - Αμινο υποκατεστημενα αναλογα διαρυλ[α,d]κυκλοεπτενιου ως μουσκαρινικοι ανταγωνιστες και μεθοδοι θεραπευτικης αγωγης των νευροψυχιατρικων διαταραχων - Google Patents
Αμινο υποκατεστημενα αναλογα διαρυλ[α,d]κυκλοεπτενιου ως μουσκαρινικοι ανταγωνιστες και μεθοδοι θεραπευτικης αγωγης των νευροψυχιατρικων διαταραχωνInfo
- Publication number
- CY1109171T1 CY1109171T1 CY20091100666T CY091100666T CY1109171T1 CY 1109171 T1 CY1109171 T1 CY 1109171T1 CY 20091100666 T CY20091100666 T CY 20091100666T CY 091100666 T CY091100666 T CY 091100666T CY 1109171 T1 CY1109171 T1 CY 1109171T1
- Authority
- CY
- Cyprus
- Prior art keywords
- dyarl
- cycloeptene
- amin
- neurotoxicity
- analogues
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
- 206010029350 Neurotoxicity Diseases 0.000 title 1
- 206010044221 Toxic encephalopathy Diseases 0.000 title 1
- 239000003149 muscarinic antagonist Substances 0.000 title 1
- 230000007135 neurotoxicity Effects 0.000 title 1
- 231100000228 neurotoxicity Toxicity 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001408 amides Chemical class 0.000 abstract 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 abstract 1
- 229960004170 clozapine Drugs 0.000 abstract 1
- 150000001933 cycloheptenes Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53192703P | 2003-12-22 | 2003-12-22 | |
| US54809004P | 2004-02-24 | 2004-02-24 | |
| US54860404P | 2004-02-27 | 2004-02-27 | |
| EP04815318A EP1696931B1 (en) | 2003-12-22 | 2004-12-21 | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109171T1 true CY1109171T1 (el) | 2014-07-02 |
Family
ID=34743692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091100666T CY1109171T1 (el) | 2003-12-22 | 2009-06-25 | Αμινο υποκατεστημενα αναλογα διαρυλ[α,d]κυκλοεπτενιου ως μουσκαρινικοι ανταγωνιστες και μεθοδοι θεραπευτικης αγωγης των νευροψυχιατρικων διαταραχων |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US7550454B2 (enExample) |
| EP (2) | EP1696931B1 (enExample) |
| JP (1) | JP2007534656A (enExample) |
| KR (1) | KR101157881B1 (enExample) |
| CN (1) | CN101962369A (enExample) |
| AT (1) | ATE426405T1 (enExample) |
| AU (1) | AU2004308955B2 (enExample) |
| BR (1) | BRPI0417749A (enExample) |
| CA (1) | CA2550735A1 (enExample) |
| CY (1) | CY1109171T1 (enExample) |
| DE (1) | DE602004020263D1 (enExample) |
| DK (1) | DK1696931T3 (enExample) |
| ES (1) | ES2324713T3 (enExample) |
| IL (1) | IL176447A0 (enExample) |
| MX (1) | MXPA06007244A (enExample) |
| NO (1) | NO20063371L (enExample) |
| NZ (1) | NZ547911A (enExample) |
| PL (1) | PL1696931T3 (enExample) |
| PT (1) | PT1696931E (enExample) |
| SG (1) | SG133606A1 (enExample) |
| SI (1) | SI1696931T1 (enExample) |
| WO (1) | WO2005063254A2 (enExample) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL151164A0 (en) | 2000-03-06 | 2003-04-10 | Acadia Pharm Inc | Azacyclic compounds for use in the treatment of serotonin related diseases |
| DE60236206D1 (de) | 2001-12-28 | 2010-06-10 | Acadia Pharm Inc | Spiroazacyclische verbindungen als monoaminrezeptormodulatoren |
| IL164155A0 (en) * | 2002-03-20 | 2005-12-18 | Teva Pharma | Crystalline forms of quetiapine hemifumarate |
| US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| MXPA04012893A (es) | 2002-06-24 | 2005-03-31 | Acadia Pharm Inc | Derivados de piperidina n-substituidos como agentes receptores de serotonina. |
| US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
| ATE407117T1 (de) | 2003-01-16 | 2008-09-15 | Acadia Pharm Inc | Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen |
| US20050250767A1 (en) * | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| US20050085463A1 (en) * | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| NZ541014A (en) * | 2003-01-23 | 2008-05-30 | Acadia Pharm Inc | Use of N-desmethylclozapine to treat schizophrenia while increasing the level of activity of a muscarinic receptor |
| NZ527142A (en) | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
| US20090239840A1 (en) * | 2003-12-22 | 2009-09-24 | Acadia Pharmaceuticals, Inc. | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS |
| WO2008021463A2 (en) * | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| ATE426405T1 (de) * | 2003-12-22 | 2009-04-15 | Acadia Pharm Inc | Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| CA2560671A1 (en) * | 2004-04-01 | 2006-01-05 | Acadia Pharmaceuticals Inc. | Crystalline forms of n-desmethylclozapine |
| US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| WO2006023852A2 (en) * | 2004-08-19 | 2006-03-02 | Vertex Pharmaceuticals, Incorporated | Modulators of muscarinic receptors |
| US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| US20060081361A1 (en) * | 2004-09-13 | 2006-04-20 | Gabbey Lawrence W | Oil cooler with integral filter |
| US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| US7868176B2 (en) | 2004-09-27 | 2011-01-11 | Acadia Pharmaceuticals, Inc. | Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation |
| MX2007006382A (es) * | 2004-11-29 | 2007-07-11 | Vertex Pharma | Moduladores de receptores muscarinicos. |
| JP2008526839A (ja) * | 2005-01-07 | 2008-07-24 | アストラゼネカ・アクチエボラーグ | １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用 |
| WO2006107948A2 (en) * | 2005-04-04 | 2006-10-12 | Acadia Pharmaceuticals Inc. | Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents |
| JP2008502707A (ja) * | 2005-04-14 | 2008-01-31 | テバ ファーマシューティカル インダストリーズ リミティド | クエチアピンフマレートの調製方法 |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| AU2006282896A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| US20080090805A1 (en) * | 2005-10-17 | 2008-04-17 | Acadia Pharmaceuticals Inc. | Cb-1 modulating compounds and their use |
| WO2007047737A1 (en) * | 2005-10-17 | 2007-04-26 | Acadia Pharmaceuticals Inc. | Cb-1 modulating compounds and their use |
| US20070106074A1 (en) * | 2005-10-17 | 2007-05-10 | Roger Olsson | Iron catalyzed cross-coupling reactions of imidoyl derivatives |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | 神経発生のｇａｂａ受容体媒介調節 |
| US20070105836A1 (en) * | 2005-10-31 | 2007-05-10 | Lars Pettersson | Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| WO2007056388A2 (en) * | 2005-11-07 | 2007-05-18 | The General Hospital Corporation | Compositions and methods for modulating poly (adp-ribose) polymerase activity |
| JP2009516705A (ja) * | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 塩の形態 |
| WO2007062339A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Liquid formulations |
| KR20080094964A (ko) | 2006-02-22 | 2008-10-27 | 버텍스 파마슈티칼스 인코포레이티드 | 무스카린성 수용체의 조절제 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
| EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| EP2037918A2 (en) * | 2006-05-15 | 2009-03-25 | Acadia Pharmaceuticals Inc. | Pharmaceutical formulations of pimavanserin |
| DE102006032426A1 (de) * | 2006-07-13 | 2008-01-17 | Neuraxpharm Arzneimittel Gmbh U. Co. Kg | Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung |
| DE102006032427A1 (de) * | 2006-07-13 | 2008-01-17 | Neuraxpharm Arzneimittel Gmbh U. Co. Kg | Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung |
| JP2010501561A (ja) * | 2006-08-18 | 2010-01-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体の調節剤 |
| US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| US20100056492A1 (en) * | 2006-12-20 | 2010-03-04 | Astrazeneca Ab | Compounds and uses thereof - 152 |
| US20100016284A1 (en) * | 2006-12-20 | 2010-01-21 | Astrazeneca Ab | Compounds and uses thereof - 151 |
| GB0701970D0 (en) | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
| CN103214473A (zh) * | 2007-03-15 | 2013-07-24 | ARYx医疗有限公司 | 二苯并[b,f][1,4]氧杂氮杂*化合物 |
| EP2134330B1 (en) | 2007-03-19 | 2013-05-08 | Acadia Pharmaceuticals Inc. | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
| AU2008307440A1 (en) * | 2007-10-03 | 2009-04-09 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| WO2009149347A1 (en) | 2008-06-05 | 2009-12-10 | President And Fellows Of Harvard College | High-valent palladium fluoride complexes and uses thereof |
| RS52703B (sr) * | 2008-06-20 | 2013-08-30 | Astrazeneca Ab | Derivat dibenzotiazepina i njegova upotreba |
| WO2010062565A1 (en) * | 2008-10-27 | 2010-06-03 | Acadia Pharmaceuticals Inc. | Muscarinic agonists |
| WO2010059943A2 (en) | 2008-11-20 | 2010-05-27 | President And Fellows Of Harvard College | Fluorination of organic compounds |
| CA2749317A1 (en) * | 2009-01-09 | 2010-07-15 | President And Fellows Of Harvard College | Fluorine containing compounds and methods of use thereof |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN101531570B (zh) * | 2009-04-17 | 2012-10-10 | 中国科学院上海有机化学研究所 | 1，2-取代-5-乙炔基-(或10，11-二氢)-5H-二苯基[a，d]环庚烯(烷)-5-醇、合成方法及用途 |
| US20110020423A1 (en) | 2009-07-22 | 2011-01-27 | Puretech Ventures | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| WO2011025748A1 (en) * | 2009-08-26 | 2011-03-03 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl [a, d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| CN103596931B (zh) | 2011-04-12 | 2016-10-12 | 哈佛大学校长及研究员协会 | 有机化合物的氟化 |
| US9273083B2 (en) | 2012-09-26 | 2016-03-01 | President And Fellows Of Harvard College | Nickel fluorinating complexes and uses thereof |
| JP6863742B2 (ja) * | 2013-09-11 | 2021-04-21 | ジ・アドミニストレーターズ・オブ・ザ・チューレーン・エデュケーショナル・ファンド | 新規アントラニルアミドとその使用 |
| US10759764B2 (en) | 2013-10-18 | 2020-09-01 | President And Fellows Of Harvard College | Fluorination of organic compounds |
| CN104016937B (zh) * | 2014-05-09 | 2016-12-07 | 中科院广州化学有限公司 | 一种n-芳基氧氮杂卓酮类化合物及其制备方法 |
| EP4585597A1 (en) * | 2015-07-02 | 2025-07-16 | F. Hoffmann-La Roche AG | Benzoxazepin oxazolidinone compounds and methods of use |
| EP3325444B1 (en) | 2015-07-20 | 2021-07-07 | Acadia Pharmaceuticals Inc. | Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| US11464768B2 (en) | 2016-12-20 | 2022-10-11 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis |
| WO2018139471A1 (ja) * | 2017-01-25 | 2018-08-02 | 大日本住友製薬株式会社 | ジベンゾジアゼピン誘導体 |
| WO2018148529A1 (en) | 2017-02-10 | 2018-08-16 | Florida A&M University | Identification of agents displaying functional activation of dopamine d2 and d4 receptors |
| US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
| CA3078289A1 (en) | 2017-10-06 | 2019-04-11 | Leyden Technologies B.V. | Stable solutions of multicyclic antidepressants |
| CN107903244B (zh) * | 2017-11-29 | 2019-06-14 | 武汉珈创生物技术股份有限公司 | 具有抗肿瘤活性的2-胺基取代苯并二氮卓化合物及其制备方法 |
| CA3089712A1 (en) | 2018-01-30 | 2019-08-08 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| JP2021104931A (ja) * | 2018-02-22 | 2021-07-26 | 大日本住友製薬株式会社 | 含窒素複素環を有するジベンゾアゼピン誘導体 |
| CN110627735A (zh) * | 2018-06-25 | 2019-12-31 | 江阴安博生物医药有限公司 | 一种新的喹硫平类似物及其制备方法和应用 |
| AU2019346626B2 (en) | 2018-09-28 | 2022-06-02 | Karuna Therapeutics, Inc. | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
| JP7696354B2 (ja) | 2019-10-21 | 2025-06-20 | アライリオン インコーポレイテッド | 睡眠障害の治療のためのＨ１および５－ＨＴ２Ａ受容体調節物質としての３－（４－（１１Ｈ－ジベンゾ［ｂ，ｅ］［１，４］アゼピン－６－イル）ピペラジン－１－イル）－プロパン酸誘導体および３－（４－（ジベンゾ［ｂ，ｆ］［１，４］オキサゼピン／チアゼピン／ジアゼピン－１１－イル）ピペラジン－１－イル）－プロパン酸誘導体 |
| CN112358455B (zh) * | 2020-11-16 | 2022-07-19 | 吉林奥来德光电材料股份有限公司 | 一种二苯并七元杂环类化合物及其制备方法与应用 |
| TWI820605B (zh) * | 2022-02-18 | 2023-11-01 | 國立臺灣大學 | 抗菌化合物、其製備方法及其用途 |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR870763A (fr) * | 1939-12-19 | 1942-03-24 | Zeiss Ikon Ag | Procédé destiné à faire disparaître les bruits produits par les boucles du film dans les appareils de prise de vues et de reproduction, en particulier pour la priseet la reproduction de films sonores |
| CH240228A (de) * | 1944-07-28 | 1945-12-15 | Ciba Geigy | Schaumisoliermasse auf Kunstharzbasis. |
| FR939591A (fr) | 1946-01-09 | 1948-11-18 | Philips Nv | Récepteur de télévision |
| FR939595A (fr) * | 1947-01-08 | 1948-11-18 | Perfectionnements apportés aux tuiles à recouvrement en matériaux de toute nature | |
| FR51M (enExample) | 1960-06-03 | 1960-11-28 | ||
| CH422793A (de) * | 1961-07-20 | 1966-10-31 | Wander Ag Dr A | Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine |
| FR1334944A (fr) * | 1961-08-11 | 1963-08-16 | Wander Ag Dr A | Procédé de préparation d'amidines de la série des 5-dibenzo-[b,e] [1,4]-diazépines |
| DE1620713A1 (de) * | 1962-05-25 | 1970-07-02 | Wander Ag Dr A | Verfahren zur Herstellung von 11-basisch substituierter Dibenzo[b,f][1,4]thiazepine |
| CH476743A (de) * | 1962-06-08 | 1969-08-15 | Wander Ag Dr A | Verfahren zur Herstellung von Amidinen der Dibenzo (b,e) (1,4)-diazepin-Reihe |
| NL140242B (nl) * | 1963-03-01 | 1973-11-15 | Wander Ag Dr A | Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen. |
| US3389139A (en) | 1963-06-14 | 1968-06-18 | Wander Ag Dr A | 6-homopiperazino and piperazinomorphanthridines |
| GB1006156A (en) | 1963-06-14 | 1965-09-29 | Wander Ag Dr A | 6-basic substituted morphanthridines |
| US3908010A (en) | 1967-03-22 | 1975-09-23 | Wander Ag Dr A | Basically substituted heterocycles as anti-emetics |
| US3884920A (en) | 1967-07-14 | 1975-05-20 | Sandoz Ag | 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines |
| AT252925B (de) | 1964-05-27 | 1967-03-10 | Wander Ag Dr A | Verfahren zur Herstellung neuer 11-basisch substituierter Dibenz[b,f][1,4]oxazepine |
| US3412193A (en) | 1965-12-13 | 1968-11-19 | American Cyanamid Co | 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility |
| US3444169A (en) | 1966-01-17 | 1969-05-13 | American Cyanamid Co | Process for 11 - aminodibenz(b,f)(1,4)oxazepines and analogous thiazepines |
| GB1184251A (en) | 1966-04-15 | 1970-03-11 | American Cyanamid Co | Oxazepines and Thiazepines |
| GB1192812A (en) | 1966-05-20 | 1970-05-20 | American Cyanamid Co | 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts |
| NL6715650A (enExample) * | 1966-12-16 | 1968-06-17 | ||
| GB1177957A (en) | 1966-12-23 | 1970-01-14 | American Cyanamid Co | Production of Oxazepines and Thiazepines |
| CA979441A (en) | 1967-02-27 | 1975-12-09 | American Cyanamid Company | 11-(piperazinyl) dibenz (b,f) (1,4) oxazepines and analogous thiazepines |
| US3852446A (en) | 1967-03-13 | 1974-12-03 | Sandoz Ag | Organic compounds in treatment of psychotic disturbances |
| DE1720007A1 (de) * | 1967-03-13 | 1971-05-19 | Wander Ag Dr A | Basisch substituierte Heterocyclen |
| CH514612A (de) | 1967-03-13 | 1971-10-31 | Wander Ag Dr A | Verfahren zur Herstellung 11-basisch substituierter Dibenz(b,f)-1,4-oxazepine und Dibenzo(b,e)-1,4-diazepine |
| US3758479A (en) | 1967-03-22 | 1973-09-11 | Sandoz Ag | Nitro and sulphamoyl substituted dibenzodiazepines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US3751415A (en) | 1967-03-22 | 1973-08-07 | Sandoz Ag | 2-nitro-11-(1-piperazinyl)-dibenz(b,f)(1,4)oxazepines |
| CA918659A (en) | 1969-07-31 | 1973-01-09 | Yoshitomi Pharmaceutical Industries | 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines |
| NL7110453A (enExample) | 1970-08-06 | 1972-02-08 | Wander Ag Dr A | |
| US3660406A (en) | 1970-10-26 | 1972-05-02 | American Cyanamid Co | 2-chloro-7-hydroxy-11-(1-piperazinyl)dibenz(b f)(1 4)oxazepines |
| CH555856A (de) | 1971-05-04 | 1974-11-15 | Hoffmann La Roche | Verfahren zur herstellung von tricyclischen verbindungen. |
| US3962248A (en) | 1972-04-04 | 1976-06-08 | Sandoz, Inc. | Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines |
| CH569730A5 (enExample) | 1972-04-04 | 1975-11-28 | Wander Ag Dr A | |
| CH585222A5 (en) | 1973-02-14 | 1977-02-28 | Wander Ag Dr A | Prepn. of antipsychotic heterocyclic piperazine derivs. - by reaction of heterocyclic ketones with metal piperazine complexes |
| NL7403657A (enExample) | 1973-03-23 | 1974-09-25 | ||
| US3983234A (en) | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
| DE2625258A1 (de) * | 1975-06-06 | 1976-12-09 | Hoffmann La Roche | Dibenzo eckige klammer auf b,f eckige klammer zu thiepinderivat |
| SE7610219L (sv) * | 1975-09-24 | 1977-03-25 | Sandoz Ag | Nya dibenso /b,e//1,4/ diazepiner |
| US4045445A (en) | 1975-12-14 | 1977-08-30 | American Cyanamid Company | 11-(4-Piperidyl)dibenzo-diazepines |
| CS179793B1 (en) | 1976-02-13 | 1977-11-30 | Miroslav Protiva | Biological derivative of 11-/4-methylpiperazino/-5h-dib)nzo/b,e/-1,4-diazepine |
| CH601288A5 (en) * | 1976-06-09 | 1978-07-14 | Sandoz Ag | 11-Piperazino-5H-di:benzodiazepine derivs. |
| CH624682A5 (enExample) | 1976-11-10 | 1981-08-14 | Sandoz Ag | |
| US4406900A (en) | 1976-11-10 | 1983-09-27 | Sandoz Ltd. | Neuroleptic use of morphanthridines |
| US4096261A (en) | 1977-02-23 | 1978-06-20 | Abbott Laboratories | Dibenzodiazepines |
| US4097597A (en) | 1977-02-23 | 1978-06-27 | Abbott Laboratories | Dibenzo b,e! 1,4!diazepines |
| US4191760A (en) | 1977-02-23 | 1980-03-04 | Abbott Laboratories | Dibenzodiazepines |
| DD133235A1 (de) * | 1977-10-10 | 1978-12-20 | Carla Rueger | Verfahren zur herstellung von in 11-stellung basisch substituierten 5h-dibenzo eckige klammer auf b,e eckige klammer zu eckige klammer auf 1,4 eckige klammer zu diazepinen |
| CS196893B1 (en) | 1977-12-22 | 1980-04-30 | Miroslav Protiva | 3-fluor-10-piperazino-8-substituted 10,11-dihydro-dibenzothiepines |
| US4263207A (en) | 1978-08-01 | 1981-04-21 | Merck & Co., Inc. | 10,11-Dihydrodibenzo[b,f][1,4]thiazepine carboxylic acids esters and amides thereof |
| US4404137A (en) * | 1979-10-16 | 1983-09-13 | Lilly Industries Limited | Pyrazolo [3,4-b][1,5]benzodiazepine compounds |
| US4663453A (en) | 1983-05-18 | 1987-05-05 | Hoechst-Roussel Pharmaceuticals Inc. | Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity |
| US4764616A (en) * | 1983-05-18 | 1988-08-16 | Hoechst-Roussel Pharmaceuticals Inc. | Benzopyrrolobenzodiazepines and quinobenzodiazepines |
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| JPH04211071A (ja) | 1990-03-05 | 1992-08-03 | Hokuriku Seiyaku Co Ltd | 多環式化合物 |
| BE1004596A4 (fr) * | 1990-09-26 | 1992-12-22 | Therabel Res S A N V | Derives de methylpiperazinoazepine, leur preparation et leur utilisation. |
| US5817655A (en) | 1991-04-23 | 1998-10-06 | Eli Lilly And Company | Methods of treatment using a thieno-benzodiazepine |
| US5300422A (en) | 1991-12-04 | 1994-04-05 | Case Western Reserve University | Screening method for controlling agranulocytosis |
| US5393752A (en) | 1992-05-26 | 1995-02-28 | Therabel Research S.A./N.V. | Methylpiperazinoazepine compounds, preparation and use thereof |
| WO1994026107A1 (en) | 1993-05-13 | 1994-11-24 | New York University | Psychosis protecting nucleic acid, peptides, compositions and method of use |
| US5354747A (en) | 1993-06-16 | 1994-10-11 | G. D. Searle & Co. | 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use |
| IL110298A (en) | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| US5538965A (en) | 1993-12-23 | 1996-07-23 | Allelix Biopharmaceuticals Inc. | Dopamine receptor ligands |
| US6566065B1 (en) | 1994-05-26 | 2003-05-20 | Mcgill University | Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene |
| GB2292685A (en) | 1994-07-27 | 1996-03-06 | Sankyo Co | Allosteric effectors at muscarinic receptors |
| US5700445A (en) | 1994-12-12 | 1997-12-23 | Allelix Biopharmaceuticals, Inc. | N-methyl piperazine compounds having dopamine receptor affinity |
| US5602124A (en) | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| US5602120A (en) | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | Benzyl-substituted compounds having dopamine receptor affinity |
| US5602121A (en) | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | Alkyl-substituted compounds having dopamine receptor affinity |
| SE9500998D0 (sv) | 1995-03-19 | 1995-03-19 | Haakan Wilhelm Wikstroem | New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics |
| GB9617305D0 (en) | 1996-08-17 | 1996-09-25 | Glaxo Wellcome Spa | Heterocyclic compounds |
| NZ507204A (en) | 1998-03-31 | 2003-12-19 | Acadia Pharm Inc | Substituted piperidine and piperazine derivatives having activity on muscarinic receptors |
| GB9924962D0 (en) | 1999-10-21 | 1999-12-22 | Mrc Collaborative Centre | Allosteric sites on muscarinic receptors |
| BR0110420A (pt) | 2000-04-28 | 2003-07-01 | Acadia Pharm Inc | Agonistas muscarìnicos |
| AU2002249885A1 (en) | 2000-11-17 | 2002-08-12 | Adolor Corporation | Delta agonist analgesics |
| US6890919B2 (en) | 2001-06-26 | 2005-05-10 | Shitij Kapur | Atypical antipsychotic agents having low affinity for the D2 receptor |
| US7355042B2 (en) | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
| DE10206941A1 (de) | 2002-02-19 | 2003-09-25 | Goetz Nowak | Neue Arzneimittel |
| WO2003082877A1 (en) | 2002-03-28 | 2003-10-09 | Eli Lilly And Company | Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders |
| CN1681388A (zh) | 2002-09-18 | 2005-10-12 | Fmc有限公司 | 三环衍生物杀虫剂 |
| US20060069083A1 (en) | 2002-12-20 | 2006-03-30 | Gerd Steiner | Pesticidal dibenzo(hetero)azepine derivatives |
| ATE407117T1 (de) | 2003-01-16 | 2008-09-15 | Acadia Pharm Inc | Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen |
| US20070275957A1 (en) | 2003-01-23 | 2007-11-29 | Weiner David M | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| NZ541014A (en) | 2003-01-23 | 2008-05-30 | Acadia Pharm Inc | Use of N-desmethylclozapine to treat schizophrenia while increasing the level of activity of a muscarinic receptor |
| WO2006017614A1 (en) | 2004-08-05 | 2006-02-16 | Acadia Pharmaceuticals Inc. | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| US20050250767A1 (en) | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| US20050085463A1 (en) | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| WO2004073639A2 (en) | 2003-02-19 | 2004-09-02 | Merck & Co. Inc. | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| DE10310196A1 (de) | 2003-03-06 | 2004-09-23 | Rina-Netzwerk Rna Technologien Gmbh | Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose |
| EP1644005B1 (en) | 2003-07-02 | 2010-08-18 | AstraZeneca AB | Metabolite of quetiapine |
| ATE426405T1 (de) | 2003-12-22 | 2009-04-15 | Acadia Pharm Inc | Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen |
| WO2005080976A1 (ja) | 2004-02-20 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法 |
| CA2560671A1 (en) | 2004-04-01 | 2006-01-05 | Acadia Pharmaceuticals Inc. | Crystalline forms of n-desmethylclozapine |
| AU2005286713B2 (en) | 2004-09-21 | 2010-10-28 | Hypnion, Inc. | Loxapine analogs and methods of use thereof |
| US20060063754A1 (en) | 2004-09-21 | 2006-03-23 | Edgar Dale M | Methods of treating a sleep disorder |
| WO2006049734A2 (en) | 2004-10-29 | 2006-05-11 | Hypnion, Inc. | Quetiapine analogs and methods of use thereof |
| US20060194769A1 (en) | 2005-01-25 | 2006-08-31 | University Of Vermont And State Agricultural College | Small molecules that reduce fungal growth |
| KR20070103499A (ko) | 2005-02-14 | 2007-10-23 | 콤비네이토릭스, 인코포레이티드 | 화합물 및 그의 이용 |
| WO2006107948A2 (en) | 2005-04-04 | 2006-10-12 | Acadia Pharmaceuticals Inc. | Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents |
| US20070105836A1 (en) | 2005-10-31 | 2007-05-10 | Lars Pettersson | Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| CN101360502B (zh) | 2005-11-18 | 2012-03-14 | 阿斯利康公司 | 结晶形式 |
| WO2007062339A2 (en) | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Liquid formulations |
| EP1951693A4 (en) | 2005-11-18 | 2012-05-30 | Astrazeneca Ab | SOLID FORMULATIONS |
| JP2009516705A (ja) | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 塩の形態 |
| WO2008002602A1 (en) | 2006-06-27 | 2008-01-03 | Acadia Pharmaceuticals Inc. | Use of n-desmethylclozapine to treat psychosis |
| WO2008066620A2 (en) | 2006-10-20 | 2008-06-05 | Concert Pharmaceuticals Inc. | Dibenzothiazepine derivatives |
-
2004
- 2004-12-21 AT AT04815318T patent/ATE426405T1/de active
- 2004-12-21 SG SG200704645-1A patent/SG133606A1/en unknown
- 2004-12-21 NZ NZ547911A patent/NZ547911A/en not_active IP Right Cessation
- 2004-12-21 WO PCT/US2004/043224 patent/WO2005063254A2/en not_active Ceased
- 2004-12-21 PT PT04815318T patent/PT1696931E/pt unknown
- 2004-12-21 PL PL04815318T patent/PL1696931T3/pl unknown
- 2004-12-21 EP EP04815318A patent/EP1696931B1/en not_active Expired - Lifetime
- 2004-12-21 US US11/019,555 patent/US7550454B2/en not_active Expired - Fee Related
- 2004-12-21 CA CA002550735A patent/CA2550735A1/en not_active Abandoned
- 2004-12-21 ES ES04815318T patent/ES2324713T3/es not_active Expired - Lifetime
- 2004-12-21 BR BRPI0417749-5A patent/BRPI0417749A/pt not_active IP Right Cessation
- 2004-12-21 JP JP2006547344A patent/JP2007534656A/ja not_active Withdrawn
- 2004-12-21 CN CN2010102389158A patent/CN101962369A/zh active Pending
- 2004-12-21 AU AU2004308955A patent/AU2004308955B2/en not_active Ceased
- 2004-12-21 SI SI200431143T patent/SI1696931T1/sl unknown
- 2004-12-21 DK DK04815318T patent/DK1696931T3/da active
- 2004-12-21 EP EP09155868A patent/EP2088147A1/en not_active Withdrawn
- 2004-12-21 MX MXPA06007244A patent/MXPA06007244A/es active IP Right Grant
- 2004-12-21 DE DE602004020263T patent/DE602004020263D1/de not_active Expired - Lifetime
- 2004-12-21 KR KR1020067014864A patent/KR101157881B1/ko not_active Expired - Fee Related
-
2006
- 2006-05-03 US US11/417,441 patent/US7491715B2/en not_active Expired - Fee Related
- 2006-05-03 US US11/417,859 patent/US7517871B2/en not_active Expired - Fee Related
- 2006-06-20 IL IL176447A patent/IL176447A0/en unknown
- 2006-07-20 NO NO20063371A patent/NO20063371L/no not_active Application Discontinuation
-
2007
- 2007-04-10 US US11/733,476 patent/US7622461B2/en not_active Expired - Fee Related
-
2009
- 2009-06-25 CY CY20091100666T patent/CY1109171T1/el unknown
- 2009-11-18 US US12/621,435 patent/US20100129473A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109171T1 (el) | Αμινο υποκατεστημενα αναλογα διαρυλ[α,d]κυκλοεπτενιου ως μουσκαρινικοι ανταγωνιστες και μεθοδοι θεραπευτικης αγωγης των νευροψυχιατρικων διαταραχων | |
| NO2020010I1 (no) | fostamatinib eller et farmasøytisk akseptabelt salt av fostamatinib, eller et hydrat, solvat eller N-oksid av fostamatinib eller det farmasøytisk akseptable saltet av fostamatinib, spesielt fostamatinib dinatrium, eventuelt på form av et hydrat | |
| CY1106645T1 (el) | Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος | |
| EE04911B1 (et) | Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks | |
| DK1525177T3 (da) | Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf | |
| WO2008021463A3 (en) | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders | |
| BR0200283A (pt) | Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios | |
| CY1107005T1 (el) | Ετεροπολυκυκλικες ενωσεις και οι χρησεις τους ως ανταγωνιστες των μεταβοτροπικων υποδοχέων του γλουταμικου | |
| DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
| CY1115484T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson | |
| EP1477482A4 (en) | NEW PHENYLALANINE DERIVATIVE | |
| IL213649A0 (en) | Prodrugs of gabapentin compounds, compositions and their use in the manufacture of a medicament | |
| DK1296671T3 (da) | Gabapentinanaloger til sövnforstyrrelser | |
| ATE399171T1 (de) | Camptothecinanaloge und deren zubereitungsmethoden | |
| DE60016460D1 (de) | Verwendungen und zusammenstellungen von nitratestern als sedativa | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| AT5708U3 (de) | Maschine zur aufnahme von schwellen eines gleises | |
| WO2004026258A3 (en) | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease | |
| PL350568A1 (en) | N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors | |
| DE502004004324D1 (de) | Maschine zur Behandlung eines Gleises | |
| DE60212487D1 (de) | Bizyklisch substituierte 4-Aminopyridopyrimidinderivate | |
| ATE375339T1 (de) | Verfahren zur herstellung von 1,3-dihydro-2h-3- benzazepin-2-on und anwendung zur herstellung von ivabradine und ihren pharmazeutischen annehmbaren salzen | |
| SE0203778D0 (sv) | A new oral immediated release dosage form | |
| BR0308753A (pt) | Método para produzir pseudo-ilhotas | |
| CY1111067T1 (el) | Χρηση της ν-(διβενζ (β,f) οξεπιν-10-υλμεθυλ) -ν-μεθυλ-ν-προπ-2-υνυλαμινης (omigapil) στην προληψη και/ή την θεραπεια της μυϊκης δυστροφiας |